Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024


Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3K?-mutated, HR+/HER2- metastatic breast cancer

View post:
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

Related Posts